METTL2A

Across TCGA pan-cancer cohorts, METTL2A RNA differs between tumor and matched normal tissue in 17 of 18 cancer types tested, making tumor–normal expression one of METTL2A’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where METTL2A RNA is more highly expressed in tumor relative to normal tissue. In most cancer types METTL2A is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

KIRP, BLCA, and LIHC are the cancer types where METTL2A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in METTL2A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRP	All	IV	+1.109	<.001	11	view →
BLCA	All	III,IV	+0.759	<.001	11	view →
LIHC	Male	III,IV	+1.052	<.001	9	view →
LUAD	Male	II,III,IV	+0.900	<.001	9	view →
THCA	All	All	−0.258	<.001	9	view →
STAD	Male	II,III,IV	+0.895	<.001	8	view →
HNSC	Male	IV	+0.883	<.001	8	view →
KICH	Female	II,III,IV	−1.237	<.001	6	view →
BRCA	All	III,IV	+0.727	<.001	6	view →
COAD	Female	II,III,IV	+0.590	<.001	6	view →
CHOL	Male	All	+1.728	<.001	5	view →
LUSC	Male	II,III,IV	+0.675	<.001	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 17 lineages.

METTL2A–KIRP

Open the KIRP breakdown →